학술논문

Serious Immune-related Adverse Events Are Associated With Greater Efficacy of Nivolumab Therapy Against Non-small Cell Lung Cancer
Document Type
Article
Source
In: In Vivo. (In Vivo, September 2023, 37(5):2229-2236)
Subject
Language
English
ISSN
17917549
0258851X